Vertex becomes first U.S. company to enter clinic with CRISPR therapy

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and partner CRISPR Therapeutics AG (NASDAQ:CRSP) have begun enrolling patients in the first U.S. company-sponsored trial using CRISPR/Cas9 editing. The European Phase

Read the full 268 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE